Targeting Bruton’s tyrosine kinase in vitreoretinal lymphoma: an open-label, prospective, single-center, phase 2 study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2162-3619
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Targeting Bruton’s tyrosine kinase in vitreoretinal lymphoma: an open-label, prospective, single-center, phase 2 study ; volume:11 ; number:1 ; day:8 ; month:11 ; year:2022 ; pages:1-5 ; date:12.2022
Experimental hematology & oncology ; 11, Heft 1 (8.11.2022), 1-5, 12.2022
- Urheber
-
Guan, Wenxue
Wang, Liang
Peng, Xiaoyan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40164-022-00354-2
- URN
-
urn:nbn:de:101:1-2023012210592353616453
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Guan, Wenxue
- Wang, Liang
- Peng, Xiaoyan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Synthesis of a Bruton’s Tyrosine Kinase Inhibitor
Editorial: Targeting bruton tyrosine kinase
Bruton´s tyrosine kinase-mediated NLRP3 phosphorylation promotes inflammasome activation
Role of Bruton’s tyrosine kinase in B cells and malignancies
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Bruton’s tyrosine kinase is a possible therapeutic target in microscopic polyangiitis
Bruton’s tyrosine kinase inhibition ameliorated neuroinflammation during chronic white matter ischemia
PROTAC for Bruton’s tyrosine kinase degradation alleviates inflammation in autoimmune diseases
Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease
Fenebrutinib, a Bruton’s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways
Second-generation inhibitors of Bruton tyrosine kinase
Synthesis of a Bruton’s Tyrosine Kinase Inhibitor
Editorial: Targeting bruton tyrosine kinase
Bruton´s tyrosine kinase-mediated NLRP3 phosphorylation promotes inflammasome activation
Role of Bruton’s tyrosine kinase in B cells and malignancies
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Bruton’s tyrosine kinase is a possible therapeutic target in microscopic polyangiitis
Bruton’s tyrosine kinase inhibition ameliorated neuroinflammation during chronic white matter ischemia
PROTAC for Bruton’s tyrosine kinase degradation alleviates inflammation in autoimmune diseases
Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease
Fenebrutinib, a Bruton’s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways
Second-generation inhibitors of Bruton tyrosine kinase
Synthesis of a Bruton’s Tyrosine Kinase Inhibitor
Editorial: Targeting bruton tyrosine kinase
Bruton´s tyrosine kinase-mediated NLRP3 phosphorylation promotes inflammasome activation
Role of Bruton’s tyrosine kinase in B cells and malignancies
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
Bruton’s tyrosine kinase is a possible therapeutic target in microscopic polyangiitis
Bruton’s tyrosine kinase inhibition ameliorated neuroinflammation during chronic white matter ischemia
PROTAC for Bruton’s tyrosine kinase degradation alleviates inflammation in autoimmune diseases
Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease
Fenebrutinib, a Bruton’s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways